SGMT
NASDAQ · Biotechnology
Sagimet Biosciences Inc-A
$10.83
+0.98 (+9.95%)
Open$9.95
Previous Close$9.85
Day High$10.86
Day Low$9.70
52W High$11.45
52W Low$4.50
Volume—
Avg Volume1.10M
Market Cap718.89M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-72.3% upside
Current
$10.83
$10.83
Target
$3.00
$3.00
$2.20
$3.00 avg
$3.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.61M | 29.26M | 29.39M |
| Net Income | 3.39M | 4.16M | 4.24M |
| Profit Margin | 11.8% | 14.2% | 14.4% |
| EBITDA | 5.59M | 5.60M | 5.84M |
| Free Cash Flow | 4.74M | 2.94M | 4.50M |
| Rev Growth | +24.7% | +14.4% | -5.6% |
| Debt/Equity | 0.41 | 0.48 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |